Secondary AML Patients Show No Increased Benefit by Adding Amonafide Instead of Daunorubicin in Cytarabine-Based Therapy - MPR
Links shared publicly online about this topic.
- 245total visits
Secondary AML Patients Show No Increased Benefit by Adding Amonafide Instead of Daunorubicin in Cytarabine-Based Therapy - MPR
empr.com —
The combination of amonafide + cytarabine does not provide a complete response benefit over treatment with daunorubicin + cytarabine in patients with secondary acute myeloid leukemia, according to a presentation at the American Society of Clinical Oncology’s 2011 Annual Meeting.
View full resource at empr.com
Tags: Leukemia, Acute Myelogenous Leukemia, News
Most Recently Shared on June 3, 2011 at 9:34 pm By:
MPR News: Secondary AML Patients Show No Increased Benefit by Adding Amonafide Instead of Daunorubicin in Cytara... http://bit.ly/lMFLoM
Advertisement
